Variables | Number | Median OS (mo) | 95Â % CI (mo) | P |
---|---|---|---|---|
Gender | 0.955 | |||
 Male | 41 | 22.7 | 6.2–39.2 |  |
 Female | 59 | 24.2 | 14.2–34.2 |  |
Age (year) | 0.608 | |||
 <60 | 71 | 22.7 | 13.4–32.0 |  |
 ≥60 | 29 | 25.9 | 7.0–44.8 |  |
Primary tumor | 0.000 | |||
 Carcinoma of the stomach | 30 | 15.7 | 10.8–20.6 |  |
 Carcinoma of the colorectum | 41 | 14.9 | 7.9–21.9 |  |
 Pseudomyxoma peritonei | 13 | Not reached | Not reached |  |
 Carcinoma of ovary and primary peritoneum | 16 | 34.6 | 22.1–47.1 |  |
Neoadjuvant chemotherapy | 0.128 | |||
 No | 53 | 31.2 | 18.4–44.0 |  |
 Yes | 47 | 20.7 | 11.6–29.8 |  |
PC timing | 0.086 | |||
 Synchronous | 80 | 27.5 | 18.1–36.9 |  |
 Metachronous | 20 | 13.2 | 10.6–15.8 |  |
PCI scores | 0.000 | |||
 ≤20 | 44 | 46.1 | 10.7–81.5 |  |
 >20 | 56 | 16.3 | 8.6–24.0 |  |
CC scores | 0.000 | |||
 0–1 | 63 | 42.9 | 28.3–57.5 |  |
 2–3 | 37 | 13.6 | 10.6–15.6 |  |
Postoperative chemotherapy cycles | 0.000 | |||
 <6 | 49 | 14.1 | 9.6–18.6 |  |
 ≥6 | 51 | 31.9 | 24.1–39.7 |  |
SAE | 0.007 | |||
 No | 86 | 31.2 | 20.5–41.9 |  |
 Yes | 14 | 12.2 | 9.5–15.0 |  |
Ascites | Â | Â | Â | 0.095 |
 ≤1000 mL | 63 | 24.2 | 13.5–34.9 |  |
 >1000 mL | 37 | 21.2 | 4.8–37.7 |  |